BCL6 PROTAC 15   Click here for help

GtoPdb Ligand ID: 11778

Synonyms: compound 15 [PMID: 30335946]
Compound class: Synthetic organic
Comment: This is a bivalent proteolysis-targeting chimera (PROTAC) molecule that promotes the degradation of the BCL6 transcription repressor protein [1]. It comprises a BCL6 binding domain linked to a thalidomide warhead that targets the bound BCL6 to the E3 ubiquitin ligase cereblon (CRBN), and on to ubiquitin-mediated proteosomal degradation. PROTAC 15 was developed by AstraZeneca for potential to treat lymphomas that are derived from germinal center B cells. Although PROTAC 15 leads to BCL6 degradation in vitro, the degradation is incomplete, and this produces only a weak antiproliferative effect on target diffuse large B-cell lymphoma (DLBCL) cells.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 19
Hydrogen bond donors 3
Rotatable bonds 17
Topological polar surface area 240.47
Molecular weight 945.34
XLogP 0.88
No. Lipinski's rules broken 2
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES O=C(CCC(=O)N1CCN2[C@H](C1)COCCOc1cc(Nc3nc2ncc3Cl)cc2c1N(C)C(=O)CC2)NCCCOCCOCCOc1cccc2c1C(=O)N(C2=O)C1CCC(=O)NC1=O
Isomeric SMILES CN1C(=O)CCc2c1c1cc(Nc3nc(ncc3Cl)N3CCN(C[C@@H]3COCCO1)C(=O)CCC(=O)NCCCOCCOCCOc1cccc3c1C(=O)N(C1CCC(=O)NC1=O)C3=O)c2
InChI InChI=1S/C45H52ClN9O12/c1-52-37(58)10-6-27-22-28-23-34(40(27)52)67-21-19-65-26-29-25-53(13-14-54(29)45-48-24-31(46)41(49-28)51-45)38(59)11-9-35(56)47-12-3-15-63-16-17-64-18-20-66-33-5-2-4-30-39(33)44(62)55(43(30)61)32-7-8-36(57)50-42(32)60/h2,4-5,22-24,29,32H,3,6-21,25-26H2,1H3,(H,47,56)(H,48,49,51)(H,50,57,60)/t29-,32?/m1/s1
InChI Key YQWUMLVLLIWGQJ-UYEDPJPISA-N
Selectivity at other protein targets
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
BCL6 transcription repressor Hs Inhibitor Inhibition 6.9 pIC50 - 1
pIC50 6.9 (IC50 1.2x10-7 M) [1]